Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions noted, no amendment — page 4

The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.

Submissions

109 documents · page 4 of 4

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-POORLY-RETAI/002Draft standard CEI-MS-19: Purity determination for peptides not…Professor Bartolomeu Nkosi-LindegaardThe standard does not require retention of the primary data
DRAFT-INCRETIN-CAR/007Draft synthesis: Cardiovascular outcomes with glucagon-like peptide-1…Vittoria YlönenDeclared interests should appear on the document rather than on a separate page
DRAFT-GASTROINTEST/001Draft synthesis: Gastrointestinal adverse events with incretin…Dr Yaa KettlewellBaseline imbalance in a small contributing trial is not remarked on
DRAFT-RENAL-OUTCOM/009Draft synthesis: Kidney outcomes with incretin receptor agonists in…Dr Constança Glendinning-UcheA sortable table implies a comparison the underlying data do not support
DRAFT-SLEEP-APNOEA/013Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaAnselm MountstephenA superseded version should remain reachable from the version that replaced it
DRAFT-COA-COMPLETE/002Draft synthesis: Completeness of certificates of analysis in the…Professor Bartolomeu Nkosi-LindegaardContributing surveys anonymise their sources to different degrees
DRAFT-COA-COMPLETE/005Draft synthesis: Completeness of certificates of analysis in the…Wilhelmina QuaresmaWhether the analyst knew the source of each sample is not reported
DRAFT-COUNTERION-C/005Draft synthesis: Counter-ion content and its effect on delivered…Dr Oswin YorkstoneWhether the analyst knew the source of each sample is not reported
DRAFT-COUNTERION-C/007Draft synthesis: Counter-ion content and its effect on delivered…Dr Eamon ImmelmannThe chain of custody between purchase and analysis is not described
DRAFT-COUNTERION-C/008Draft synthesis: Counter-ion content and its effect on delivered…Professor Bartolomeu Nkosi-LindegaardContributing surveys anonymise their sources to different degrees
DRAFT-COUNTERION-C/010Draft synthesis: Counter-ion content and its effect on delivered…Ivo MountstephenA superseded version should remain reachable from the version that replaced it
DRAFT-RUSSIAN-REGI/002Draft synthesis: Nationally registered neuropeptides and the…Stellan Cholmondeley-AdeA superseded version should remain reachable from the version that replaced it
DRAFT-RUSSIAN-REGI/008Draft synthesis: Nationally registered neuropeptides and the…Dr Wojciech Kaltenbach-MensahA sortable table implies a comparison the underlying data do not support
DRAFT-SPONSOR-COND/004Draft synthesis: The consequences of a wholly sponsor-generated…Dr Emiliana OllerenshawDeclared interests should appear on the document rather than on a separate page
DRAFT-AMYLIN-ANALO/007Draft synthesis: Amylin analogues as monotherapy and in combinationAnselm MountstephenA superseded version should remain reachable from the version that replaced it
DRAFT-RECONSTITUTI/008Draft synthesis: Reconstitution practice and delivered doseDr Quentin EnthovenDeclared interests should appear on the document rather than on a separate page
DRAFT-PANCREATITIS/005Draft synthesis: Acute pancreatitis with incretin-based therapiesDr Georgiana MountstephenDeclared interests should appear on the document rather than on a separate page
DRAFT-TIRZEPATIDE-/005Draft synthesis: Tirzepatide compared with semaglutide in type 2…Dr Yaa KettlewellBaseline imbalance in a small contributing trial is not remarked on
DRAFT-MITOCHONDRIA/008Draft synthesis: Mitochondria-targeted peptides in bioenergetic…Vittoria YlönenDeclared interests should appear on the document rather than on a separate page

page 4 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.